Merck suits up for another Opdivo showdown with Keytruda liver cancer approval
Merck just advanced the Keytruda-Opdivo immuno-oncology rivalry into a brand-new arena. On Friday, the FDA handed Keytruda a new approval in patients with hepatocellular carcinoma—the most common form of liver cancer in adults—who have already been treated with Bayer’s Nexavar. That’s a group for which regulators cleared Opdivo, Keytruda’s chief nemesis in the PD-1/PD-L1 class,… Read More »